Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) FCF Margin (2020 - 2025)

Historic FCF Margin for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to 9716.67%.

  • Ovid Therapeutics' FCF Margin fell 10421000.0% to 9716.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 580.84%, marking a year-over-year decrease of 5548800.0%. This contributed to the annual value of 9909.89% for FY2024, which is 17936800.0% up from last year.
  • As of Q3 2025, Ovid Therapeutics' FCF Margin stood at 9716.67%, which was down 10421000.0% from 76.53% recorded in Q2 2025.
  • Ovid Therapeutics' 5-year FCF Margin high stood at 77.21% for Q1 2021, and its period low was 114348.52% during Q3 2022.
  • Moreover, its 5-year median value for FCF Margin was 8492.31% (2024), whereas its average is 13734.95%.
  • Over the last 5 years, Ovid Therapeutics' FCF Margin had its largest YoY gain of 1051265000bps in 2023, and its largest YoY loss of -161358000bps in 2023.
  • Ovid Therapeutics' FCF Margin (Quarter) stood at 5.5% in 2021, then increased by 24bps to 4.18% in 2022, then dropped by -28bps to 5.34% in 2023, then tumbled by -162339bps to 8674.57% in 2024, then fell by -12bps to 9716.67% in 2025.
  • Its FCF Margin stands at 9716.67% for Q3 2025, versus 76.53% for Q2 2025 and 7923.08% for Q1 2025.